Abstract
The idiotype of myeloma immunoglobulin can be used as a unique tumour-specific antigen. We tested the hypothesis that tumour antigen-specific immunity can be transferred from bone-marrow-transplant donor to recipient. We immunised a healthy sibling donor with myeloma immunoglobulin from the plasma of the recipient, conjugated to an immunogenic carrier protein and emulsified in an adjuvant, before marrow transplantation. Detection of a lymphoproliferative response, a parallel response in the carrier protein, recovery of a recipient CD4+ T-cell line with unique specificity for myeloma idiotype, and demonstration by in-situ hybridisation that the cell line was of donor origin, proved that a myeloma idiotype-specific T-cell response was successfully transferred to the recipient. Donor immunisation with myeloma idiotype may represent a new strategy for enhancing the specific antitumour effect of allogeneic marrow grafts.
Original language | English (US) |
---|---|
Pages (from-to) | 1016-1020 |
Number of pages | 5 |
Journal | The Lancet |
Volume | 345 |
Issue number | 8956 |
DOIs | |
State | Published - Apr 22 1995 |
ASJC Scopus subject areas
- General Medicine